AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...

Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...